Angiotensin-converting enzyme inhibitor-induced angioedema

Cutis

Volumn 91, Issue 1, 2013, Pages 30-35

  Theyab, Abduljabar A ^a   Lee, David S ^b   Khachemoune, Amor ^c  

^a UNIVERSITY OF ANBAR   (Iraq)

^b LAC USC MEDICAL CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ANGIONEUROTIC EDEMA; ARTICLE; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; HUMAN; PATHOPHYSIOLOGY; RISK FACTOR;

ANGIOEDEMA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; HUMANS; RISK FACTORS;

EID: 84875293234     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Byrd JB, Adam A, Brown NJ. Angiotensin-converting enzyme inhibitor-associated angioedema. Immunol Allergy Clin North Am. 2006;26:725-737.
2. Katzung BG, Masters S, Trevor A, eds. Basic & Clinical Pharmacology. 11th ed. New York, NY: McGraw-Hill; 2009.
3. Inman WH, Rawson NS, Wilton LV, et al. Postmarketing surveillance of enalapril. I: results of prescription-event monitoring. BMJ. 1988;297:826-829.
4. Slater EE, Merrill DD, Guess HA, et al. Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition. JAMA. 1988;260:967-970.
5. Kostis JB, Packer M, Black HR, et al. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens. 2004;17:103-111.
6. Cordes B. Angioedema of the head and neck. Presented at: Veteran Affairs Medical Center Grand Rounds; December 22, 2005; Houston, TX.
7. Milton JL. On giant urticaria. Edinburgh Med J. 1876;22:513-526. Cited by: Cicardi M, Agostoni A. Hereditary angioedema. N Engl J Med. 1996;334:1666-1667.
8. Quincke H. Uber akutes umschreibenes hautodem. Monatsschr Prakt Dermatol. 1882;1:129.
9. Wilkin JK, Hammond JJ, Kirkendall WM. The captopril-induced eruption. a possible mechanism: cutaneous kinin potentiation. Arch Dermatol. 1980;116:902-905.
10. Cicardi M, Zingale LC, Bergamaschini L, et al. Angioedema associated with angiotensin-converting enzyme inhibitor use: outcome after switching to a different treatment. Arch Intern Med. 2004;164:910-913.
11. Jackson EK. Renin and angiotensin. In: Brunton LL, Lazo JS, Parker KL, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 11th ed. New York, NY: McGraw-Hill; 2006:789-822.
12. Bönner G, Preis S, Schunk U, et al. Hemodynamic effects of bradykinin on systemic and pulmonary circulation in healthy and hypertensive humans. J Cardiovasc Pharmacol. 1990;15(suppl 6):S46-S56.
13. Burrell LM. A risk-benefit assessment of losartan potassium in the treatment of hypertension. Drug Saf. 1997;16:56-65.
14. Sharma PK, Yium JJ. Angioedema associated with angiotensin II receptor antagonist losartan. South Med J. 1997;90:552-553.
15. Foreman JC. Neuropeptides and the pathogenesis of allergy. Allergy. 1987;42:1-11.
16. Cascieri MA, Bull HG, Mumford RA, et al. Carboxyl-terminal tripeptidyl hydrolysis of substance P by purified rabbit lung angiotensin-converting enzyme and the potentiation of substance P activity in vivo by captopril and MK-422. Mol Pharmacol. 1984;25:287-293.
17. Yokosawa H, Endo S, Ohgaki Y, et al. Hydrolysis of substance P and its analogs by angiotensin-converting enzyme from rat lung. characterization of endopeptidase activity of the enzyme. J Biochem. 1985;98:1293-1299.
18. Emanueli C, Grady EF, Madeddu P, et al. Acute ACE inhibition causes plasma extravasation in mice that is mediated by bradykinin and substance P. Hypertension. 1998;31:1299-1304.
19. Byrd JB, Touzin K, Sile S, et al. Dipeptidyl pepti- dase IV in angiotensin-converting enzyme inhibitor associated angioedema [published online ahead of print November 19, 2007]. Hypertension. 2008;51:141-147.
20. Duan QL, Nikpoor B, Dube MP, et al. A variant in XPNPEP2 is associated with angioedema induced by angiotensin I-converting enzyme inhibitors [published online ahead of print September 1, 2005]. Am J Hum Genet. 2005;77:617-626.
21. Lindgren BR, Anderson CD, Andersson RG. Potentiation of inflammatory reactions in guinea-pig skin by an angiotensin converting enzyme inhibitor (MK 422). Eur J Pharmacol. 1987;135:383-387.
22. Andersson RG, Karlberg BE, Lindgren BR, et al. Enalaprilat, but not cilazaprilat, increases inflammatory skin reactions in guinea-pigs. Drugs. 1991;41(suppl 1):48-53.
23. Anderson MW, deShazo RD. Studies of the mechanism of angiotensin-converting enzyme (ACE) inhibitor-associated angioedema: the effect of an ACE inhibitor on cutaneous responses to bradykinin, codeine, and histamine. J Allergy Clin Immunol. 1990;85:856-858.
24. Caspritz G, Alpermann HG, Schleyerbach R. Influence of the new angiotensin converting enzyme inhibitor ramipril on several models of acute inflammation and the adjuvant arthritis in the rat. Arzneimittelforschung. 1986;36:1605-1608.
25. Frank MM, Gelfand JA, Atkinson JP. Hereditary angioedema: the clinical syndrome and its management. Ann Intern Med. 1976;84:580-593.
26. Kelemen Z, Moldovan D, Mihály E, et al. Baseline level of functional C1-inhibitor correlates with disease severity scores in hereditary angioedema [published online ahead of print November 27, 2009]. Clin Immunol. 2010;134:354-358.
27. Sigler C, Annis K, Cooper K, et al. Examination of baseline levels of carboxypeptidase N and complement components as potential predictors of angioedema associated with the use of an angiotensin-converting enzyme inhibitor. Arch Dermatol. 1997;133:972-975.
28. Kleiner GI, Giclas P, Stadtmauer G, et al. Unmasking of acquired autoimmune C1-inhibitor deficiency by an angiotensin-converting enzyme inhibitor. Ann Allergy Asthma Immunol. 2001;86:461-464.
29. Gelée B, Michel P, Haas R, et al. Angiotensin-converting enzyme inhibitor-related angioedema: emergency treatment with complement C1 inhibitor concentrate [in French; published online ahead of print November 29, 2007]. Rev Med Interne. 2008;29:516-519.
30. Nielsen EW, Gramstad S. Angioedema from angiotensin-converting enzyme (ACE) inhibitor treated with complement 1 (C1) inhibitor concentrate. Acta Anaesthesiol Scand. 2006;50:120-122.
31. Cambien F, Alhenc-Gelas F, Herbeth B, et al. Familial resemblance of plasma angiotensin-converting enzyme level: the Nancy Study. Am J Hum Genet. 1988;43:774-780.
32. Mathews KP, Pan PM, Gardner NJ, et al. Familial carboxypeptidase N deficiency. Ann Intern Med. 1980;93:443-445.
33. Simmons BB, Folsom MA, Bryden LA, et al. Angioedema after local trauma in a patient on angiotensin-converting enzyme inhibitor therapy. J Am Board Fam Med. 2008;21:577-579.
34. Warin RP. The role of trauma in the spreading weals of hereditary angio-oedema. Br J Dermatol. 1983;108:189-194.
35. Sarkar P, Nicholson G, Hall G. Brief review: angiotensin converting enzyme inhibitors and angioedema: anesthetic implications. Can J Anaesth. 2006;53:994-1003.
36. Banerji A, Clark S, Blanda M, et al. Multicenter study of patients with angiotensin-converting enzyme inhibitor-induced angioedema who present to the emergency department. Ann Allergy Asthma Immunol. 2008;100:327-332.
37. Pigman EC, Scott JL. Angioedema in the emergency department: the impact of angiotensin-converting enzyme inhibitors. Am J Emerg Med. 1993;11:350-354.
38. Cicardi M, Conciato L, Agostoni A. Angioedema due to angiotensin-converting enzyme inhibition: an association frequently unrecognized. Ann Ital Med Int. 1997;12:8-10.
39. Weiner JM. Failure to recognise the association of life-threatening angio-oedema and angiotensin-converting enzyme inhibitor therapy. Aust N Z J Med. 1995;25:241-242.
40. Finley CJ, Silverman MA, Nunez AE. Angiotensin-converting enzyme inhibitor-induced angioedema: still unrecognized. Am J Emerg Med. 1992;10:550-552.
41. Grant NN, Deeb ZE, Chia SH. Clinical experience with angiotensin-converting enzyme inhibitor-induced angioedema. Otolaryngol Head Neck Surg. 2007;137:931-935.
42. Kostis JB, Shelton B, Gosselin G, et al. Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD). SOLVD investigators. Am Heart J. 1996;131:350-355.
43. Mahoney EJ, Devaiah AK. Angioedema and angiotensin-converting enzyme inhibitors: are demographics a risk? Otolaryngol Head Neck Surg. 2008;139:105-108.
44. Ono H, Kawaguchi H, Ishii N, et al. A point mutation in exon 7 of the C1-inhibitor gene causing type I hereditary angioedema. Hum Genet. 1996;98:452-453.
45. Orfan N, Patterson R, Dykewicz MS. Severe angioedema related to ACE inhibitors in patients with a history of idiopathic angioedema. JAMA. 1990;264:1287-1289.
46. Hedner T, Samuelsson O, Lindholm L, et al. Precipitation of angioedema by antihypertensive drugs. J Hypertens Suppl. 1991;9:S360-S361.
47. Jain M, Armstrong L, Hall J. Predisposition to and late onset of upper airway obstruction following angiotensin-converting enzyme inhibitor therapy. Chest. 1992;102:871-874.
48. Peacock ME, Brennan WA, Strong SL, et al. Angioedema as a complication in periodontal surgery: report of a case. J Periodontol.1991;62:643-645.
49. Byrne TJ, Douglas DD, Landis ME, et al. Isolated visceral angioedema: an underdiagnosed complication of ACE inhibitors?. Mayo Clin Proc. 2000;75:1201-1204.
50. Mullins RJ, Shanahan TM, Dobson RT. Visceral angioedema related to treatment with an ACE inhibitor. Med J Aust. 1996;165:319-321.
51. Jardine DL, Anderson JC, McClintock AD. Delayed diagnosis of recurrent visceral angio-oedema secondary to ACE inhibitor therapy. Aust N Z J Med. 1999;29:377-378.
52. Arakawa M, Murata Y, Rikimaru Y, et al. Drug-induced isolated visceral angioneurotic edema. Intern Med. 2005;44:975-978.
53. Dobbels P, Van Overbeke L, Vanbeckevoort D, et al. Acute abdomen due to intestinal angioedema induced by ACE inhibitors: not so rare? Acta Gastroenterol Belg. 2009;72:455-457.
54. Winters M; American Academy of Emergency Medicine. Clinical practice guideline: initial evaluation and management of patients presenting with acute urticaria or angioedema. http://www.aaem.org/em-resources/position- statements/2006/clinical-practice-guidelines. Published July 10, 2006. Accessed December 19, 2012.
55. Agostoni A, Cicardi M. Drug-induced angioedema without urticaria. Drug Saf. 2001;24:599-606.
56. Haymore BR, Yoon J, Mikita CP, et al. Risk of angioedema with angiotensin receptor blockers in patients with prior angioedema associated with angiotensin-converting enzyme inhibitors: a meta-analysis. Ann Allergy Asthma Immunol. 2008;101:495-499.
57. Bas M, Greve J, Stelter K, et al. Therapeutic efficacy of icatibant in angioedema induced by angiotensin- converting enzyme inhibitors: a case series [published online ahead of print May 5, 2010]. Ann Emerg Med. 2010;56:278-282.
58. Brown NJ. Effectiveness of bradykinin receptor blocker at reducing swelling associated with angiotensin converting enzyme (ACE) inhibitor-associated angioedema .clinicaltrials.gov Identifier: NCT00517582. http://clinicaltrials.gov/ct2/show/NCT00517582?term=icatibant&rank=8. Published August 15, 2007. Updated July 24, 2009. Accessed December 19, 2012.
59. Bas M. Amelioration of angiotensin converting enzyme inhibitor induced angioedema study. clinicaltrials.gov Identifier: NCT01154361. http://clinicaltrials.gov/ct2 /show/NCT01154361?term=NCT01154361&rank=1. Published June 29, 2010. Updated December 22, 2011. Accessed December 19, 2012.
60. Brown NJ. Effect of bradykinin receptor antagonism on ACE inhibitor-associated angioedema. clinicaltrials.gov Identifier: NCT01574248. http://clinicaltrials.gov/ct2/show/NCT01574248?term=ICATIBANT&rank=10. Published December 14, 2011. Updated December 8, 2012. Accessed December 19, 2012.
61. Christiansen SC, Zuraw BL. Update on therapeutic developments for hereditary angioedema. Allergy Asthma Proc. 2009;30:500-505.